Keyword: Deerfield Management
Deerfield Management committed up to $80 million to fund a new center at the Dana-Farber Cancer Institute set on exploring protein degradation.
Appello Pharmaceuticals raised $10.5 million to fund its glutamate-modulating Parkinson’s disease treatment licensed from Vanderbilt University.
Metacrine raised $65 million to launch phase 1 testing of its FXR agonist in NASH and gastrointestinal diseases later this month.
Gregory Verdine’s FogPharma raised $66 million in series B financing, with hopes to bring its first product to the clinic by the end of next year.
Dracen will advance drugs that stifle a tumor's energy source and boost the immune response to cancer.
Chondrial Therapeutics has secured a near $23 million raise, led by VC Deerfield Management, and has taken on Deerfield’s adviser Carole Ben-Maimon as its new president and CEO.